NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Sector Expert: David Lewis

Morgan Stanley



Recent Quotes

"This looks to be another strong year for ISRG's revenue and procedure growth."

— David Lewis, Morgan Stanley (1/29/13)
more >

"Growth remains above 20% in Diagnostics for HAE."

— David Lewis, Morgan Stanley (10/30/12)
more >

"Quarterly volatility in ISRG results could provide a more attractive entry point."

— David Lewis, Morgan Stanley (9/28/12)
more >

"Receipt of the CE Mark validates benefits of HAE's Solx technology."

— David Lewis, Morgan Stanley (9/18/12)
more >

"HAE has multiple levers it can pull to drive earnings growth."

— David Lewis, Morgan Stanley (8/3/12)
more >

"The Pall deal may help commercialize HAE's whole blood solution."

— David Lewis, Morgan Stanley (4/30/12)
more >

"HAE's top-line guidance was consistent with our ~6% growth in FY13."

— David Lewis, Morgan Stanley (1/31/12)
more >



Due to permission requirements, not all quotes are shown.